Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans

Diabetes

Volumn 64, Issue 4, 2015, Pages 1193-1201

  Van De Weijer, Tineke ^a,b   Phielix, Esther ^a,c   Bilet, Lena ^a,b   Williams, Evan G ^d   Ropelle, Eduardo R ^d   Bierwagen, Alessandra ^c   Livingstone, Roshan ^c   Nowotny, Peter ^c   Sparks, Lauren M ^a,b   Paglialunga, Sabina ^a,b   Szendroedi, Julia ^c,e   Havekes, Bas ^a,b   Moullan, Norman ^d   Pirinen, Eija ^d,f   Hwang, Jong Hee ^c   Schrauwen Hinderling, Vera B ^a,b   Hesselink, Matthijs K C ^a,b   Auwerx, Johan ^d   Roden, Michael ^c,e   Schrauwen, Patrick ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^d EPFL   (Switzerland)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIMIGRAINE AGENT; ATORVASTATIN; CHOLESTEROL; FATTY ACID; INSULIN; LIPID; METFORMIN; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; OMEPRAZOLE; PLACEBO; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL; URICOSURIC AGENT; ANTILIPEMIC AGENT; PYRAZINE DERIVATIVE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EX VIVO STUDY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN SENSITIVITY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MITOCHONDRIAL GENE; MITOCHONDRIAL RESPIRATION; MITONUCLEAR PROTEIN IMBALANCE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE MITOCHONDRION; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REBOUND; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; UNFOLDED PROTEIN RESPONSE; CLINICAL TRIAL; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY;

CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; PYRAZINES;

EID: 84962030356     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0667     Document Type: Article

References (43)

1. Sirtori CR, Gianfranceschi G, Sirtori M, et al. Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis. Atherosclerosis 1981;38: 267-271
2. Taskinen MR, Nikkilä EA. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. Atherosclerosis 1988;69: 249-255
3. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 2005;54: 3148-3153
4. Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C, DeFronzo RA, Mandarino LJ. Paradoxical changes in muscle gene expression in insulinresistant subjects after sustained reduction in plasma free fatty acid concentration. Diabetes 2007;56: 743-752
5. Phielix E, Jelenik T, Nowotny P, Szendroedi J, Roden M. Reduction of nonesterified fatty acids improves insulin sensitivity and lowers oxidative stress, but fails to restore oxidative capacity in type 2 diabetes: A randomised clinical trial. Diabetologia 2014;57: 572-581
6. Schrauwen P, Schrauwen-Hinderling V, Hoeks J, Hesselink MK. Mitochondrial dysfunction and lipotoxicity. Biochim Biophys Acta 2010;1801: 266-271
7. Phielix E, Schrauwen-Hinderling VB, Mensink M, et al. Lower intrinsic ADPstimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes 2008;57: 2943-2949
8. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002;51: 2944-2950
9. Szendroedi J, Schmid AI, Chmelik M, et al. Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 2007;4: E154
10. Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 1994;78: 717-721
11. Saloranta C, Taskinen MR, Widen E, Härkönen M, Melander A, Groop L. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993;42: 1559-1566
12. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor Vitamins in human nutrition. Annu Rev Nutr 2008;28: 115-130
13. Cantó C, Houtkooper RH, Pirinen E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat dietinduced obesity. Cell Metab 2012;15: 838-847
14. Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013;154: 430-441
15. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice. Cell Metab 2011;14: 528-536
16. Benyó Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115: 3634-3640
17. Kuipers H, Verstappen FT, Keizer HA, Geurten P, van Kranenburg G. Variability of aerobic performance in the laboratory and its physiologic correlates. Int J Sports Med 1985;6: 197-201
18. Siri WE. The gross composition of the body. Adv Biol Med Phys 1956;4: 239-280
19. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-E223
20. Mensink M, Blaak EE, van Baak MA, Wagenmakers AJ, Saris WH. Plasma free fatty acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes. Diabetes 2001;50: 2548-2554
21. Brehm A, Krssak M, Schmid AI, Nowotny P, Waldhäusl W, Roden M. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes 2006;55: 136-140
22. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983;55: 628-634
23. Bergström J, Hermansen L, Hultman E, Saltin B. Diet, muscle glycogen and physical performance. Acta Physiol Scand 1967;71: 140-150
24. Koopman R, Schaart G, Hesselink MK. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol 2001;116: 63-68
25. Houtkooper RH, Mouchiroud L, Ryu D, et al. Mitonuclear protein imbalance as a conserved longevity mechanism. Nature 2013;497: 451-457
26. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545-15550
27. Bai P, Cantó C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 2012;16: 290-295
28. Bai P, Canto C, Brunyánszki A, et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab 2011;13: 450-460
29. Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009;458: 1056-1060
30. Ramsey KM, Yoshino J, Brace CS, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 2009;324: 651-654
31. Stingl H, Krssák M, Krebs M, et al. Lipid-dependent control of hepatic glycogen stores in healthy humans. Diabetologia 2001;44: 48-54
32. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959;82: 420-430
33. Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Eriksson J, Taskinen MR. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes. Diabet Med 1993;10: 950-957
34. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97: 2859-2865
35. Pirinen E, Cantó C, Jo YS, et al. Pharmacological Inhibition of poly(ADPribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014;19: 1034-1041
36. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988;37: 1020-1024
37. Bolli GB. The dawn phenomenon: Its origin and contribution to early morning hyperglycemia in diabetes mellitus. Diabete Metab 1988;14: 675-686
38. Shapiro ET, Polonsky KS, Copinschi G, et al. Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab 1991;72: 444-454
39. Hoeks J, Hesselink MK, Russell AP, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: Acute effect of fatty acids. Diabetologia 2006;49: 2419-2426
40. Hoeks J, van Herpen NA, Mensink M, et al. Prolonged fasting identifies skeletal muscle mitochondrial dysfunction as consequence rather than cause of human insulin resistance. Diabetes 2010;59: 2117-2125
41. Heilbronn LK, de Jonge L, Frisard MI, et al.; Pennington CALERIE Team. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. JAMA 2006;295: 1539-1548
42. Meex RC, Schrauwen-Hinderling VB, Moonen-Kornips E, et al. Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. Diabetes 2010;59: 572-579
43. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14: 612-622